Rallybio Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
25
- Stock Symbol
-
RLYB
- Investments
-
2
- Share Price
-
$1.11
- (As of Friday Closing)
Rallybio General Information
Description
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
Contact Information
Website
www.rallybio.comCorporate Office
- 234 Church Street
- Suite 1020
- New Haven, CT 06510
- United States
Corporate Office
- 234 Church Street
- Suite 1020
- New Haven, CT 06510
- United States
Rallybio Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.11 | $1.10 | $1.08 - $4.60 | $46.1M | 41.5M | 75.9K | -$1.77 |
Rallybio Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | (38,294) | (30,629) | 116,771 | 119,542 |
| Revenue | 299 | 0 | 0 | 0 |
| EBITDA | (79,151) | (80,561) | (68,450) | (45,443) |
| Net Income | (73,881) | (74,564) | (66,654) | (47,013) |
| Total Assets | 92,431 | 115,620 | 180,435 | 182,185 |
| Total Debt | 284 | 392 | 555 | 0 |
Rallybio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Rallybio Comparisons
Industry
Financing
Details
Rallybio Competitors (48)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| SAGE Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Gyroscope | Formerly VC-backed | London, United Kingdom | ||||
| Ember Therapeutics | Formerly VC-backed | New York, NY | ||||
| Oncorus | Formerly VC-backed | Andover, MA |
Rallybio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Rallybio Executive Team (10)
| Name | Title | Board Seat |
|---|---|---|
| Stephen Uden MD | Co-Founder, Chief Executive Officer & Board Member | |
| Ami Bavishi | Executive Director and Head of Investor Relations and Corporate Communications | |
| Carrie White | Executive Director, Corporate Development & Financial Planning | |
| Laura Ekas Ph.D | Senior Vice President and Head of Corporate & Commercial Strategy | |
| Claire Hernon | Associate Director of Corporate Strategy & New Product Planning |
Rallybio Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Christine Nash | Self | Board Member | |
| Helen Boudreau | Self | Board Member | |
| Hui Liu Ph.D | Self | Board Member | |
| Ketan Patel MD | F-Prime Capital | Board Member | |
| Kush Parmar Ph.D | 5AM Ventures | Board Member |
Rallybio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Rallybio Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Rallybio Investments & Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Prophylix | 22-Aug-2019 | Biotechnology | |||
| RE Ventures | 23-Jul-2019 | Joint Venture | Drug Discovery |
Rallybio Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Prophylix | Biotechnology | Tromso, Norway |
Rallybio ESG
Risk Overview
Risk Rating
Updated May, 24, 2023
22.03 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,009
Rank
Percentile
Commercial Services
Industry
of 475
Rank
Percentile
Business Support Services
Subindustry
of 186
Rank
Percentile
Rallybio FAQs
-
When was Rallybio founded?
Rallybio was founded in 2018.
-
Who is the founder of Rallybio?
Stephen Uden MD and Jeffrey Fryer are the founders of Rallybio.
-
Who is the CEO of Rallybio?
Stephen Uden MD is the CEO of Rallybio.
-
Where is Rallybio headquartered?
Rallybio is headquartered in New Haven, CT.
-
What is the size of Rallybio?
Rallybio has 25 total employees.
-
What industry is Rallybio in?
Rallybio’s primary industry is Drug Discovery.
-
Is Rallybio a private or public company?
Rallybio is a Public company.
-
What is Rallybio’s stock symbol?
The ticker symbol for Rallybio is RLYB.
-
What is the current stock price of Rallybio?
As of 04-Oct-2024 the stock price of Rallybio is $1.11.
-
What is the current market cap of Rallybio?
The current market capitalization of Rallybio is $46.1M.
-
What is Rallybio’s current revenue?
The trailing twelve month revenue for Rallybio is $299K.
-
Who are Rallybio’s competitors?
NGM Biopharmaceuticals, SAGE Therapeutics, Gyroscope, Ember Therapeutics, and Oncorus are some of the 48 competitors of Rallybio.
-
What is Rallybio’s annual earnings per share (EPS)?
Rallybio’s EPS for 12 months was -$1.77.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
